An observational study in HIV Infections, HIV-1-infection and HIV-2 Infection, sponsored by Erasmus Medical Center. Active, not recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-13.
Sponsored by Erasmus Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in HIV Infections with a site in Netherlands — 6 open to participants now, 10 under way, 2 of them phase 3. HIV Infections · Netherlands.
Among the 86 studies in HIV Infections with a site in Netherlands, this one is the 9th largest by enrollment of the 10 observational ones that give a count, is one of 3 that started in 2021, is one of 10 observational ones, and was the 77th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →6 of the 86 studies in HIV Infections with a site in Netherlands are open now. Recruiting first, the newest first:
ViiV Healthcare · Sites in Netherlands
Ages 18–55 · Healthy volunteers
Casper Rokx · Sites in Netherlands, Belgium, France and 7 more countries
Ages 18+ · Healthy volunteers
Prof. Jan Prins · Sites in Netherlands
Ages 18+
Erasmus Medical Center · Sites in Netherlands
Ages 18+
Radboud University Medical Center · Sites in Netherlands, Belgium, Germany and 4 more countries
Ages 18+ · Women only
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 17 · Phase 3 31 · Phase 4 15
First in 2000; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 200 across 781 observational studies indexed under HIV Infections.
Median enrollment 206 across the 74 interventional studies, 330 across the 10 observational. Of the 67 that completed or were terminated, 28 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 86 have an industry lead sponsor. The 10 most frequent:
Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.
Erasmus Medical Center has 5 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in HIV Infections with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00825929Radboud University Medical CenterPharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women. | 2026-12 |
| NCT04888754Erasmus Medical CenterA Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the Netherlands | 2027-01 |
| NCT07053384ViiV HealthcareA Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV | 2027-01-22 |
Add all 3 to your calendar (.ics) → With an account.
Among the 86 studies in HIV Infections with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A prospective non-interventional cohort study at Erasmus MC of adult chronic HIV infected patients of ≥18 years of age who initiate antiretroviral therapy in routine care.
HIV cannot be cured with the current treatment armamentarium. A reservoir of latently HIV infected long lived CD4+T-cells is present in patients with HIV that are not affected by antiretroviral therapy. The evolution of this reservoir after therapy initiation is ill understood, as are the potential strategies to eradicate this reservoir. This study aims to anticipate on future HIV cure strategies by building a cohort to study ex vivo the reservoirs of HIV patients, the obstacles to cure HIV, and new therapeutic compounds and strategies.
Main study parameters/endpoints:
A project from the Erasmus MC HIV Eradication Group (EHEG).
Patients are 18 years or older with a confirmed HIV infection without prior exposure to cART (treatment naïve). Prior use of pre-exposure prophylaxis is allowed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Major comorbidities:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To develop a prospective cohort in the Netherlands of chronic HIV infected patients within-depth reservoir characterization for future cure interventions.
The HIV latent reservoir will be characterised in chronic HIV patients using novel techniques like FISH-flow
Time frame: 5-10 years
To study the evolution of the HIV reservoir and immune host responses over time during antiretroviral therapy.
The HIV reservoir will be characterised over time to study the dynamics of the reservoir
Time frame: 5-10 years
To explore established and putative new interventions aimed at curing HIV.
Blood and leucapheresis samples will be collected for testing of HIV cure drugs
Time frame: 5-10 years
To explore differences in reservoir size, activity and host responses, and their relation with clinical characteristics, between patients with different dominant HIV subtypes and sexes.
Blood and leucapheresis samples will be collected for reservoir characterisation to compare reservoirs between patients
Time frame: 5-10 years
To compare and validate new reservoir assays with current established assays.
Blood and leucapheresis samples will be collected to compare and validate new reservoir assays
Time frame: 5-10 years
Plan to share: Undecided — No definitive decision on this yet. This will also depend on confidentiality.
No publications or documents are linked to this record.
Started May 2021 (actual). Primary completion is estimated for Jan 2027, 68 months after the start.
Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 68 months is above that.
Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.